
Choisissez votre étiquette
affichée directement sur le flaconReta + Cagri Blend
GLP-1
- Expédié depuis l'Allemagne
Commande
- DHL avec suivi
- Emballage discret
En un coup d'œil
Reta + Cagri Blend en chiffres
Les chiffres clés de notre lexique.
Article complet du lexique- Class
- Triple agonistGLP-1 / GIP / glucagon, + amylin analog
- Half-life
- Retatrutide around 6 dayscagrilintide around 7 to 8 days
- Form
- Lyophilisatepowder, reconstituted with BAC water
- Sizes
- 30 mg1 size in the shop
What studies show
All 5 sources in the lexicon- up to24.2 %Jastreboff et al., NEJM, 2023
- Sanyal et al., Nature Medicine, 2024
- Lau et al., The Lancet, 2021
Avis
Ce que disent les clients
Uniquement des commandes réelles qui contenaient Reta + Cagri Blend.
Tous les avisIl n'existe pas encore d'analyse de laboratoire pour Reta + Cagri Blend. Votez pourFaites-le tester vous-même, nous payons la moitiéToutes les analyses de laboratoire
Connaissances
Tout sur Reta + Cagri Blend
Informations détaillées bientôt disponibles.
Dosage
Chargement des informations de dosage …
Bon à avoir
Ce dont vous avez besoin avec
L'eau bactériostatique est ajoutée automatiquement à votre panier. Seringues et tampons en un clic.
Seringues à insuline
10 pièces · 5.50 €
Tampons alcoolisés
50 pièces · 10 €
Combien d'eau ?
Unités sur la seringue pour la taille de votre flacon.
Ouvrir le calculateur →Is the Reta + Cagri Blend approved or studied?
No. As of 26 October 2026 the registry ClinicalTrials.gov lists no trial with Retatrutide and cagrilintide together. Both components are in phase 3 and not approved.
Why Retatrutide and cagrilintide together?
Both act on different satiety pathways: Retatrutide on GLP-1, GIP and glucagon, cagrilintide on amylin receptors. With semaglutide as the partner, weight loss in a phase 1b trial after 20 weeks was 17.1 instead of 9.8 percent. For Retatrutide as the partner there are no data.
What do the studies of the components show?
Retatrutide alone: in TRIUMPH-1 after 80 weeks 25.0 percent less body weight on average at the highest study dose, 3.9 percent on placebo. Cagrilintide alone: up to 10.8 percent after 26 weeks in phase 2, 3.0 percent on placebo. In a substudy liver fat also fell sharply on Retatrutide.
Why is the cagrilintide share so small?
The vial contains five times as much Retatrutide as cagrilintide, because Retatrutide is the stronger and limiting part. Anyone going by the Retatrutide share stays far below the amounts used in the cagrilintide trials. Whether the small share contributes anything has not been studied.
How long do the components stay in the body?
Retatrutide had a half-life of about six days in a phase 1b study, cagrilintide 159 to 195 hours in another study, so about a week. Both fit one dose per week.
Which side effects were seen with the components?
With both, mainly gastrointestinal effects such as nausea and diarrhoea, depending on the dose. On Retatrutide heart rate rose in a dose-dependent way in phase 2. Two satiety signals together may strengthen nausea at the start, this has not been measured for this blend.
Which trials are still running?
Nine phase 3 trials of Retatrutide are running, the largest on heart and kidney events until 2029. The RENEW trials of cagrilintide alone run until 2027. No trial of the blend is listed in the registry.
Produits associés
Produits similaires
Tirzepatide
Peptides · GLP-1 & perte de graisse GLP-1 & perte de graisse
10 tailles
Testé en laboratoire
= dès 10 €/fiole
Retatrutide
Peptides · GLP-1 & perte de graisse GLP-1 & perte de graisse
11 tailles
Testé en laboratoire
= dès 16 €/fiole
Semaglutide
Peptides · GLP-1 & perte de graisse GLP-1 & perte de graisse
6 tailles
Testé en laboratoire
= dès 10 €/fiole
Mazdutide
Peptides · GLP-1 & perte de graisse GLP-1 & perte de graisse
2 tailles
= dès 32 €/fiole
Reta + Cagri Blend